Recombinant Mesocricetus auratus Peroxiredoxin-5, mitochondrial (PRDX5)

What is the basic structure and function of Mesocricetus auratus PRDX5?

Mesocricetus auratus (Golden Syrian hamster) PRDX5 is a member of the peroxiredoxin family of antioxidant enzymes that differs significantly from other peroxiredoxins in its enzymatic mechanism, high affinity for organic peroxides and peroxynitrite, and wide subcellular distribution . The protein exists in two main forms: a full-length 24 kDa form that targets exclusively to mitochondria (translated from the first AUG codon) and a shorter 17 kDa form with cytoplasmic and nuclear localization (translated from the second AUG codon) .

The N-terminal 50 amino acids of the full-length PRDX5 are essential for mitochondrial targeting, where it provides remarkable cytoprotection against oxidative stress . Like other peroxiredoxins, PRDX5 contains conserved catalytic cysteine residues essential for its peroxidase activity, with specific structural elements that facilitate interactions with target substrates and reduce reactive oxygen species.

How does PRDX5 differ from other peroxiredoxin family members?

PRDX5 distinguishes itself from other peroxiredoxin family members in several key aspects:

• Enzymatic mechanism: PRDX5 utilizes an atypical 2-Cys mechanism that differs from the typical 2-Cys mechanism of PRDX1-4 and the 1-Cys mechanism of PRDX6 .

• Substrate preference: PRDX5 demonstrates particularly high affinity for organic peroxides and peroxynitrite compared to other family members .

• Subcellular distribution: Unlike other peroxiredoxins that typically localize to specific compartments, PRDX5 exhibits a broader distribution across mitochondria, cytoplasm, and nucleus .

• Structure: PRDX5 forms a stable decamer in its oxidized state, similar to human peroxiredoxin IV, while other family members may have different oligomerization patterns .

These unique characteristics position PRDX5 as a versatile antioxidant with specialized functions in cellular defense mechanisms.

What expression systems are most effective for producing recombinant Mesocricetus auratus PRDX5?

For producing recombinant Mesocricetus auratus PRDX5, both prokaryotic and eukaryotic expression systems have proven effective, each with specific advantages:

• Bacterial expression systems (E. coli):

  • Typically yield high quantities of protein

  • Can be used with various tags (His, GST) for purification

  • Examples include BL21(DE3) strains with pET vector systems

  • Most suitable for biochemical and structural studies

• Mammalian expression systems:

  • Provide proper post-translational modifications

  • Better for functional studies requiring native protein folding

  • Essential for subcellular localization studies of the mitochondrial isoform

  • Can be used with epitope tags for detection and purification

The choice of expression system should be guided by the specific research questions. For high-yield production of PRDX5 for enzymatic assays or structural studies, bacterial systems are often preferred. For studies investigating mitochondrial targeting or protein-protein interactions in a mammalian context, mammalian expression systems may be more appropriate despite their typically lower yields.

What are the critical considerations for purifying active recombinant PRDX5?

Purification of active recombinant Mesocricetus auratus PRDX5 requires careful attention to several critical factors:

• Maintaining reducing conditions: The catalytic cysteines of PRDX5 are susceptible to oxidation, which can affect activity. Including reducing agents (DTT or β-mercaptoethanol) throughout purification is essential .

• pH considerations: PRDX5 activity is pH-dependent, with optimal activity typically observed at physiological pH. Purification buffers should maintain appropriate pH levels.

• Protein stability: PRDX5 can form different oligomeric states depending on its oxidation status. For consistent preparations, standardize oxidation conditions during purification.

• Activity verification: Peroxidase activity should be verified using established assays. The specific activity of recombinant PRDX5 should be comparable to that of human PrxII (approximately 1.2 μmol min⁻¹ mg⁻¹) or human Prx-IV (approximately 1.6 μmol min⁻¹ mg⁻¹) .

• Storage conditions: Purified PRDX5 should be stored with reducing agents to prevent oxidative inactivation, preferably at -80°C with cryoprotectants to minimize freeze-thaw damage.

A typical purification workflow includes affinity chromatography (utilizing His or GST tags), followed by size exclusion chromatography to separate different oligomeric forms, with activity testing at each stage.

What methods are most reliable for measuring PRDX5 peroxidase activity?

Several reliable methods have been established for measuring PRDX5 peroxidase activity:

• Thioredoxin-coupled assay:

  • Measures NADPH oxidation at 340 nm

  • Requires purified thioredoxin, thioredoxin reductase, and NADPH

  • Can determine specific activity in μmol min⁻¹ mg⁻¹

  • Widely used for comparing activity across different peroxiredoxins

• Direct peroxide consumption assay:

  • Quantifies the decrease in peroxide concentration

  • Can use various detection methods (FOX assay, PeroXOquant)

  • Suitable for testing different peroxide substrates

• Competitive inhibition assays:

  • Measures competition with other peroxidases (e.g., horseradish peroxidase)

  • Useful for inhibitor screening and comparative studies

For accurate activity measurements, researchers should:

• Include appropriate controls (inactive mutants like C49A/C73A/C170A)

• Ensure linear reaction kinetics within the assay timeframe

• Validate results using multiple complementary methods

How do inhibitors like conoidin A affect PRDX5 activity and what structural insights have been gained?

Inhibitors like conoidin A (2,3-bis(bromomethyl)quinoxaline-1,4-dioxide) and its derivatives provide valuable insights into PRDX5 structure and function:

Mechanism of inhibition:

• Alkylation of catalytic cysteines: Conoidin A covalently modifies the peroxidatic and resolving cysteines through its reactive bromine groups .

• Crosslinking of active site: The inhibitor can create crosslinks between catalytic cysteines, locking PRDX5 in the "locally unfolded" conformation .

• Possible irreversible oxidation: Conoidin A may promote irreversible oxidation of catalytic cysteines to sulfinic or sulfonic acid forms .

Structural insights gained:

• Crystal structures of oxidized PRDX5 reveal a disulfide-linked decameric structure .

• A helix macrodipole near the active site increases the reactivity of catalytic cysteines to conoidin A .

• Conoidin A maintains the enzyme in the "locally unfolded" conformation, distinct from the "fully folded" state .

Inhibition profile:

• IC₅₀ values for conoidin A are similar across peroxiredoxins (PRDX5: 374 μM, human PrxII: 358 μM, human PrxIV: 262 μM) .

• Conoidin compounds lack specificity for hookworm versus human peroxiredoxins, suggesting need for further optimization .

These findings provide a foundation for developing more specific inhibitors targeting unique features of PRDX5, potentially leading to therapeutic applications.

How does mitochondrial PRDX5 protect against oxidative stress and regulate apoptosis?

Mitochondrial PRDX5 provides significant cytoprotection through multiple interconnected mechanisms:

• Direct ROS detoxification:

  • Efficiently neutralizes hydrogen peroxide and organic peroxides produced during mitochondrial respiration .

  • Provides first-line defense against oxidative damage to mitochondrial DNA, proteins, and lipids.

• Regulation of calcium homeostasis:

  • Overexpression of mitochondrial PRDX5 blocks increases in intracellular Ca²⁺ during oxidative stress .

  • Prevents Ca²⁺-dependent activation of calpains and subsequent Bax cleavage .

  • Modulates calcium transport between mitochondria and endoplasmic reticulum, particularly through inositol 1,4,5-trisphosphate receptors (IP₃R) .

• Inhibition of mitochondria-dependent apoptosis:

  • Prevents activation of caspase-9, a key initiator of the intrinsic apoptotic pathway .

  • Protects against mitochondrial DNA damage induced by stressors like MPP⁺ .

  • Maintains mitochondrial membrane integrity under oxidative stress conditions.

• Redox-based signaling:

  • May participate in redox regulation of mitochondrial proteins involved in energy metabolism and quality control.

  • Could influence mitochondrial dynamics through redox-sensitive GTPases.

These protective mechanisms are particularly relevant in neurodegenerative contexts, where mitochondrial dysfunction and oxidative stress are central to pathogenesis.

What is the relationship between PRDX5 expression and mitochondrial biogenesis?

The expression of PRDX5 is intricately linked with mitochondrial biogenesis through coordinated transcriptional regulation:

• Promoter architecture:

  • The PRDX5 promoter contains binding sites for Nuclear Respiratory Factor 1 (NRF-1) and GABPA (also called Nuclear Respiratory Factor 2) .

  • These transcription factors are master regulators of mitochondrial biogenesis .

  • Luciferase reporter assays demonstrate that basal PRDX5 promoter activity largely depends on these NRF-1 and GABPA sites .

• Evolutionary conservation:

  • The NRF-1 and GABPA binding sites in the PRDX5 promoter are conserved across six mammalian genomes (human, chimpanzee, cow, mouse, rat, and dog) .

  • This conservation suggests fundamental importance in coordinating PRDX5 expression with mitochondrial function.

• Functional integration:

  • High basal expression of the PRDX5 gene is coordinated with the expression of nuclear genes encoding mitochondrial proteins .

  • This coordination ensures adequate antioxidant protection during mitochondrial biogenesis, when ROS production may increase.

This relationship highlights the integration of PRDX5 into broader cellular programs regulating mitochondrial homeostasis and suggests that PRDX5 expression should be considered in the context of mitochondrial biogenesis in experimental designs.

How can recombinant PRDX5 be used to investigate neurodegenerative disease mechanisms?

Recombinant Mesocricetus auratus PRDX5 serves as a valuable tool for investigating neurodegenerative disease mechanisms through several experimental approaches:

• Neuroprotection studies:

  • Overexpression of mitochondrial PRDX5 in neuronal cell lines treated with neurotoxins like MPP⁺ (which mimics Parkinson's disease) .

  • Assessment of cell viability, mitochondrial function, and apoptotic markers.

  • Investigation of mechanisms underlying neuroprotection.

• Mitochondrial dysfunction models:

  • PRDX5 overexpression or knockdown in cellular models of mitochondrial dysfunction.

  • Measurement of mitochondrial membrane potential, respiration, and ROS production.

  • Analysis of mitochondrial DNA damage and repair processes .

• Calcium dysregulation studies:

  • Investigation of PRDX5's role in modulating calcium signaling between ER and mitochondria .

  • Monitoring calcium fluxes using fluorescent indicators under oxidative stress conditions.

  • Assessment of calcium-dependent enzyme activation (e.g., calpains) and downstream events .

• Pharmacological studies:

  • Testing protective effects of compounds that upregulate or mimic PRDX5 function.

  • Screening for molecules that enhance mitochondrial PRDX5 activity.

  • Using PRDX5 inhibitors to understand the consequences of impaired antioxidant defense in neurodegenerative contexts.

These approaches provide insights into how mitochondrial oxidative stress and calcium dysregulation contribute to neurodegeneration, potentially leading to novel therapeutic strategies targeting mitochondrial redox biology.

What is the potential role of PRDX5 in cancer models and how might it be targeted therapeutically?

PRDX5 has emerging significance in cancer research, particularly in hormone-dependent malignancies:

• Role in castration-resistant prostate cancer (CRPC):

  • PRDX5 is upregulated in drug-tolerant persister (DTP) cells following androgen receptor (AR) inhibitor treatment .

  • The thioredoxin/peroxiredoxin pathway is generally upregulated in these resistant cells .

  • PRDX5 promotes AR inhibitor resistance and CRPC development .

• Therapeutic targeting potential:

  • Inhibition of PRDX5 suppresses DTP cell proliferation in culture .

  • PRDX5 inhibition dampens CRPC development in animal models .

  • Clinical observations suggest PRDX5 inhibition may stabilize PSA progression and metastatic lesions in patients .

• Mechanisms of action in cancer:

  • May protect cancer cells from oxidative stress-induced apoptosis.

  • Could regulate redox-sensitive signaling pathways driving proliferation.

  • Might influence metabolic adaptations supporting cancer cell survival.

• Therapeutic approaches:

  • Development of specific PRDX5 inhibitors based on structural insights.

  • Combination therapies targeting PRDX5 alongside standard treatments.

  • Biomarker development to identify patients likely to benefit from PRDX5-targeting strategies.

These findings suggest that PRDX5 inhibition represents a novel concept and potential therapeutic strategy for managing treatment-resistant cancers, particularly CRPC . Future research should focus on developing more specific inhibitors and understanding the precise mechanisms through which PRDX5 promotes cancer cell survival.

How does Mesocricetus auratus PRDX5 compare structurally and functionally to PRDX5 from other species?

Comparative analysis reveals important insights into the conservation and divergence of PRDX5 across species:

• Sequence and structural conservation:

  • Mammalian PRDX5 proteins share high sequence identity (typically >85% among rodents and humans) .

  • The catalytic peroxidatic and resolving cysteine residues are invariably conserved across species .

  • The thioredoxin fold domain is highly conserved, while C-terminal regions show greater variation .

• Functional similarity:

  • The core peroxidase activity is preserved across species, with comparable specific activities .

  • Human PrxII, human PrxIV, and hookworm AcePrx-1 demonstrate similar peroxidase activities (1.182, 1.616, and 1.640 μmol min⁻¹ mg⁻¹, respectively) .

  • Similar sensitivity to inhibitors like conoidin A (IC₅₀ values: AcePrx-1: 374 μM, hPrxII: 358 μM, hPrxIV: 262 μM) .

• Regulatory conservation:

  • The PRDX5 promoter contains conserved NRF-1 and GABPA binding sites across multiple mammalian species (human, chimpanzee, cow, mouse, rat, and dog) .

  • This suggests evolutionary conservation of transcriptional regulation mechanisms linking PRDX5 to mitochondrial biogenesis.

• Species differences:

  • Parasitic species like Ancylostoma ceylanicum show greater divergence in sequence, particularly in the C-terminal tail region .

  • Expression patterns vary, with AcePrx-1 predominantly expressed in adult hookworms rather than egg or larval stages .

This comparative perspective provides valuable context for interpreting experimental findings across different model systems and understanding the fundamental importance of PRDX5 in cellular redox biology.

What can expression patterns of PRDX5 across development tell us about its functional significance?

Developmental expression patterns of PRDX5 provide important insights into its functional roles:

• Differential expression across developmental stages:

  • In parasitic species like Ancylostoma ceylanicum, peroxiredoxin (AcePrx-1) shows substantially higher expression in adult worms compared to egg and larval stages (37- and 24-fold higher, respectively) .

  • Western blot analysis confirms this pattern, with protein levels in egg and larval stages below detection limits .

  • This suggests stage-specific functions that may relate to different metabolic demands or environmental exposures.

• Tissue-specific expression patterns:

  • PRDX5 exhibits variable expression across tissues, reflecting tissue-specific roles.

  • The presence in excretory/secretory products of some organisms suggests potential extracellular functions .

  • Methodological approaches to study these patterns include real-time PCR analysis of cDNA populations from different developmental stages and tissues .

• Subcellular localization during development:

  • The full-length form (24 kDa) of human PRDX5 targets exclusively to mitochondria, while the shorter form (17 kDa) localizes to cytoplasm and nucleus .

  • This differential targeting may vary during development as cellular energy demands and ROS production patterns change.

  • Understanding these patterns requires immunohistochemistry with specific antibodies and subcellular fractionation studies.

These expression patterns suggest that PRDX5 plays context-specific roles that may evolve throughout development, potentially reflecting changing requirements for antioxidant protection, signaling modulation, or specialized functions in different tissues and developmental stages.

How do post-translational modifications affect PRDX5 function and how can they be detected?

Post-translational modifications (PTMs) significantly impact PRDX5 function through multiple mechanisms:

• Oxidative modifications:

  • Oxidation of peroxidatic cysteine to sulfenic, sulfinic, or sulfonic acid forms affects catalytic activity .

  • Disulfide formation between peroxidatic and resolving cysteines is part of the catalytic cycle .

  • Hyperoxidation can lead to enzyme inactivation and structural changes .

  • Detection methods: Redox-state specific antibodies, mass spectrometry, non-reducing gel electrophoresis.

• Structural consequences:

  • Oxidation drives transition from "fully folded" to "locally unfolded" conformations .

  • The C-terminal tail (residues 171-196) becomes disordered in the locally unfolded conformation .

  • Crystal structures reveal that oxidation can promote formation of disulfide-linked decamers .

  • Detection methods: X-ray crystallography, circular dichroism, limited proteolysis.

• Circadian oscillations:

  • Peroxiredoxin proteins undergo oxidation-reduction cycles with circadian periodicity .

  • These oscillations have been observed in red blood cells from different organisms (humans and mice) .

  • Detection methods: Western blotting with careful sample preparation using N-ethylmaleimide (NEM) to prevent post-lysis oxidation .

• Other potential modifications:

  • Phosphorylation may affect enzyme activity or subcellular localization.

  • Acetylation could regulate mitochondrial PRDX5 function.

  • Detection methods: Phospho-specific antibodies, acetylation antibodies, mass spectrometry.

Understanding these modifications provides insights into the complex regulation of PRDX5 function and its integration into cellular signaling networks.

What role might PRDX5 play in calcium signaling between mitochondria and endoplasmic reticulum?

PRDX5 plays a significant role in regulating calcium signaling between mitochondria and endoplasmic reticulum (ER):

• Crosstalk between organelles:

  • Mitochondria and ER operate in tandem to regulate intracellular Ca²⁺ fluxes in various cellular processes, including neurodegenerative mechanisms .

  • PRDX5 appears to modulate this communication, potentially through redox regulation of calcium transport proteins.

• Experimental evidence:

  • Overexpression of mitochondrial PRDX5 blocks increases in intracellular Ca²⁺ during oxidative stress .

  • PRDX5 overexpression prevents Ca²⁺-dependent activation of calpains and subsequent Bax cleavage .

  • Using calcium channel inhibitors (Nimodipine, Dantrolene, and 2-APB), researchers determined that Ca²⁺ release arises primarily from ER stores through 1,4,5-inositol-trisphosphate receptors (IP₃R) .

• Proposed mechanisms:

  • PRDX5 may maintain redox homeostasis necessary for proper calcium channel function.

  • It could directly or indirectly regulate the oxidation state of critical thiols in calcium channels or transporters.

  • Protection against mitochondrial dysfunction may preserve calcium buffering capacity.

• Methodological approaches:

  • Calcium imaging using fluorescent indicators in cells with modulated PRDX5 expression.

  • Pharmacological manipulation with calcium channel inhibitors to identify specific pathways.

  • Analysis of calcium-dependent enzyme activation (e.g., calpains) as downstream readouts.

This emerging role positions PRDX5 as a potential modulator of mitochondria-ER communication through redox-dependent mechanisms, with important implications for understanding cellular responses to stress and potential therapeutic interventions.

What are the current challenges and future directions in PRDX5 research?

Current challenges and future directions in PRDX5 research span several interrelated areas:

• Structural and mechanistic understanding:

  • Obtaining crystal structures of PRDX5 in different oxidation states and bound to physiological substrates.

  • Characterizing the specific interactions between PRDX5 and thioredoxin systems in mitochondria.

  • Developing more specific inhibitors based on structural insights, potentially targeting unique features of the C-terminal region .

• Physiological roles:

  • Defining the precise contributions of PRDX5 to mitochondrial homeostasis versus other antioxidant systems.

  • Understanding tissue-specific functions and compensatory mechanisms.

  • Characterizing non-peroxidase functions, such as chaperone activity or signaling roles.

• Disease relevance:

  • Clarifying the role of PRDX5 in neurodegenerative diseases, where mitochondrial dysfunction and disruption of Ca²⁺ homeostasis are implicated .

  • Validating PRDX5 as a therapeutic target in cancer, particularly castration-resistant prostate cancer .

  • Investigating potential roles in other conditions involving oxidative stress and mitochondrial dysfunction.

• Methodological advances:

  • Developing better tools to detect and quantify PRDX5 oxidation states in living cells.

  • Creating more specific antibodies and activity-based probes.

  • Establishing improved animal models with tissue-specific PRDX5 modulation.

• Translational opportunities:

  • Developing PRDX5-targeting therapeutics for conditions where its inhibition or enhancement would be beneficial.

  • Identifying biomarkers associated with PRDX5 function for diagnostic or prognostic applications.

  • Exploring the potential of PRDX5 as an immunomodulatory agent based on its presence in excretory/secretory products .

Addressing these challenges will advance our understanding of PRDX5 biology and potentially lead to novel therapeutic strategies for diseases involving mitochondrial dysfunction and oxidative stress.

How might recombinant PRDX5 be used as a tool for novel therapeutic development?

Recombinant PRDX5 offers multiple avenues for therapeutic development:

• Drug discovery platform:

  • High-throughput screening of chemical libraries against recombinant PRDX5 to identify novel inhibitors.

  • Structure-based drug design targeting specific features of PRDX5.

  • Development of conoidin A derivatives with improved specificity and potency .

  • Validation of hits in cellular and animal models, such as castration-resistant prostate cancer models .

• Therapeutic protein development:

  • Engineered PRDX5 variants with enhanced stability or catalytic efficiency.

  • Cell-penetrating PRDX5 formulations for delivery to specific tissues.

  • PRDX5 conjugates targeting specific cell types or subcellular compartments.

• Biomarker applications:

  • Development of assays to measure PRDX5 activity or oxidation state in clinical samples.

  • Correlation of PRDX5 status with disease progression or treatment response.

  • Potential use as a companion diagnostic for PRDX5-targeting therapies.

• Immunomodulatory applications:

  • Investigation of PRDX5's potential role in immune responses, based on observations of peroxiredoxins in parasite excretory/secretory products .

  • Development of PRDX5-based immunotherapies or vaccines.

• Disease-specific approaches:

  • For neurodegenerative diseases: Enhancement of mitochondrial PRDX5 function to protect against oxidative stress and calcium dysregulation .

  • For cancer: Inhibition of PRDX5 to sensitize resistant cancer cells to treatment .

  • For parasitic infections: Targeting parasite-specific features of peroxiredoxins while sparing host enzymes .

These diverse applications highlight the potential of recombinant PRDX5 as both a research tool and a platform for therapeutic development across multiple disease contexts.